bupivacaine has been researched along with Migraine Disorders in 26 studies
Bupivacaine: A widely used local anesthetic agent.
1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.
bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with migraine of moderate or severe intensity were randomized to receive bilateral GONB with each side administered 3 mL of bupivacaine 0." | 2.94 | A Randomized, Double-Dummy, Emergency Department-Based Study of Greater Occipital Nerve Block With Bupivacaine vs Intravenous Metoclopramide for Treatment of Migraine. ( Bijur, PE; Del Valle, M; Friedman, BW; Gallagher, EJ; Harrilal, MA; Irizarry, E; Robbins, MS; Solorzano, C; Williams, A; Zias, E, 2020) |
| "Sixty acute migraine attack patients were assigned to 3 groups of 20 patients each." | 2.87 | The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. ( Cevik, Y; Çorbacioglu, ŞK; Dagar, S; Emektar, E; Korucu, O, 2018) |
| "Patients with acute migraine who reported persistence of a moderate or severe headache for at least 1 hour or longer after treatment with 10 mg of intravenous metoclopramide were randomized to bilateral GONB with a total of 6 mL of 0." | 2.87 | A Randomized, Sham-Controlled Trial of Bilateral Greater Occipital Nerve Blocks With Bupivacaine for Acute Migraine Patients Refractory to Standard Emergency Department Treatment With Metoclopramide. ( Friedman, BW; Irizarry, E; John Gallagher, E; Mohamed, S; Pearlman, S; Robbins, MS; Tarsia, V, 2018) |
| "They were allowed a stable dose of migraine preventive medications that was maintained throughout the study." | 2.80 | A double-blind, placebo-controlled study of repetitive transnasal sphenopalatine ganglion blockade with tx360(®) as acute treatment for chronic migraine. ( Cady, R; Dexter, K; Manley, HR; Saper, J, 2015) |
| "Subjects were allowed a stable dose of migraine preventive medications that was maintained throughout the study." | 2.80 | Long-term efficacy of a double-blind, placebo-controlled, randomized study for repetitive sphenopalatine blockade with bupivacaine vs. saline with the Tx360 device for treatment of chronic migraine. ( Cady, RJ; Cady, RK; Dexter, K; Manley, HR; Saper, J, 2015) |
| "50 patients diagnosed with migraine were included in our study." | 1.72 | Are more nerve injections in the same session more effective in migraine treatment? 3-month follow-up results. ( Pak, AT; Sengul, Y; Üstün, İ, 2022) |
| "The outcomes observed were migraine pain before and after administration within the same initial encounter of receiving an occipital nerve block using a numeric pain rating scale, injection direction, medications used, duration of effect and frequency of additional injections, and adverse reactions." | 1.56 | Evaluation of Occipital Nerve Blocks for Acute Pain Relief of Migraines. ( Dang, T; Ebied, AM; Nguyen, DT, 2020) |
| "In chronic migraine patients undergoing Greater occipital nerve (GON) block, mean number of days with pain per month before and after block, mean duration of pain in attacks (in hours), and mean Visual Analog Scale (VAS) in attack and pain severity were recorded from files." | 1.46 | Do bilateral and unilateral greater occipital nerve block effectiveness differ in chronic migraine patients? ( Ataç-Uçar, C; İnan, LE; Ünal-Artık, HA; Yoldaş, TK, 2017) |
| "Ten women suffering from migraine diagnosed according to International Headache Society criteria were evaluated in a six-month study period." | 1.35 | Greater occipital nevre block in migraine headache: preliminary results of 10 patients. ( Başar, H; Inan, L; Inan, N; Takmaz, SA; Uçler, S; Yazar, MA, 2008) |
| "The pathophysiology of many types of chronic headaches is not well understood." | 1.33 | Cervicogenic headache in patients with presumed migraine: missed diagnosis or misdiagnosis? ( Cook, AJ; Hamill-Ruth, RJ; Rowlingson, JC; Yi, X, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.85) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (19.23) | 29.6817 |
| 2010's | 14 (53.85) | 24.3611 |
| 2020's | 6 (23.08) | 2.80 |
| Authors | Studies |
|---|---|
| Karaoğlan, M | 2 |
| İnan, LE | 4 |
| Üstün, İ | 1 |
| Pak, AT | 1 |
| Sengul, Y | 1 |
| Ebied, AM | 1 |
| Nguyen, DT | 1 |
| Dang, T | 1 |
| Friedman, BW | 2 |
| Irizarry, E | 2 |
| Williams, A | 1 |
| Solorzano, C | 1 |
| Zias, E | 1 |
| Robbins, MS | 2 |
| Harrilal, MA | 1 |
| Del Valle, M | 1 |
| Bijur, PE | 1 |
| Gallagher, EJ | 1 |
| Oswald, JC | 1 |
| Schuster, NM | 1 |
| Korucu, O | 1 |
| Dagar, S | 1 |
| Çorbacioglu, ŞK | 1 |
| Emektar, E | 1 |
| Cevik, Y | 1 |
| Mohamed, S | 1 |
| Tarsia, V | 1 |
| Pearlman, S | 1 |
| John Gallagher, E | 1 |
| Smith, JH | 1 |
| Potter, JL | 1 |
| Robblee, JV | 1 |
| Cady, R | 1 |
| Saper, J | 2 |
| Dexter, K | 2 |
| Manley, HR | 2 |
| Dilli, E | 1 |
| Halker, R | 1 |
| Vargas, B | 1 |
| Hentz, J | 1 |
| Radam, T | 1 |
| Rogers, R | 1 |
| Dodick, D | 1 |
| Inan, N | 2 |
| Karadaş, Ö | 2 |
| Gül, HL | 2 |
| Erdemoğlu, AK | 1 |
| Türkel, Y | 1 |
| Akyol, A | 1 |
| Cady, RK | 1 |
| Cady, RJ | 1 |
| Cohen, SP | 1 |
| Peterlin, BL | 1 |
| Fulton, L | 1 |
| Neely, ET | 1 |
| Kurihara, C | 1 |
| Gupta, A | 1 |
| Mali, J | 1 |
| Fu, DC | 1 |
| Jacobs, MB | 1 |
| Plunkett, AR | 1 |
| Verdun, AJ | 1 |
| Stojanovic, MP | 1 |
| Hanling, S | 1 |
| Constantinescu, O | 1 |
| White, RL | 1 |
| McLean, BC | 1 |
| Pasquina, PF | 1 |
| Zhao, Z | 1 |
| Okmen, K | 1 |
| Dagistan, Y | 1 |
| Dagistan, E | 1 |
| Kaplan, N | 1 |
| Cancan, E | 1 |
| Cuadrado, ML | 1 |
| Aledo-Serrano, Á | 1 |
| Navarro, P | 1 |
| López-Ruiz, P | 1 |
| Fernández-de-Las-Peñas, C | 1 |
| González-Suárez, I | 1 |
| Orviz, A | 1 |
| Fernández-Pérez, C | 1 |
| Ozon, AO | 1 |
| Koc, G | 1 |
| Ünal-Artık, HA | 1 |
| Ataç-Uçar, C | 1 |
| Yoldaş, TK | 1 |
| Saracco, MG | 1 |
| Valfrè, W | 1 |
| Cavallini, M | 1 |
| Aguggia, M | 1 |
| Cortijo, E | 1 |
| Guerrero-Peral, ÁL | 1 |
| Herrero-Velázquez, S | 1 |
| Mulero, P | 1 |
| Pedraza, M | 1 |
| Barón, J | 1 |
| de la Cruz, C | 1 |
| Ruiz, M | 1 |
| Campos-Blanco, DM | 1 |
| Marco-Llorente, J | 1 |
| Rojo-Martínez, E | 1 |
| Fernández, R | 1 |
| Rozin, L | 1 |
| Rozin, R | 1 |
| Koehler, SA | 1 |
| Shakir, A | 1 |
| Ladham, S | 1 |
| Barmada, M | 1 |
| Dominick, J | 1 |
| Wecht, CH | 1 |
| Mellick, LB | 1 |
| Mellick, GA | 1 |
| Yi, X | 1 |
| Cook, AJ | 1 |
| Hamill-Ruth, RJ | 1 |
| Rowlingson, JC | 1 |
| Ashkenazi, A | 1 |
| Matro, R | 1 |
| Shaw, JW | 1 |
| Abbas, MA | 1 |
| Silberstein, SD | 1 |
| Takmaz, SA | 1 |
| Uçler, S | 1 |
| Yazar, MA | 1 |
| Inan, L | 1 |
| Başar, H | 1 |
| Sjaastad, O | 1 |
| Aasly, J | 1 |
| Fredriksen, T | 1 |
| Wysocka Bakowska, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acute Headache Treatment in Pregnancy: Improvement in Pain Scores With Occipital Nerve Block vs PO Acetaminophen With Caffeine A Randomized Controlled Trial[NCT03951649] | Phase 4 | 62 participants (Actual) | Interventional | 2020-02-10 | Completed | ||
| Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache[NCT05365880] | Phase 2 | 20 participants (Anticipated) | Interventional | 2022-03-23 | Recruiting | ||
| Use of the Tx360 Nasal Applicator for Transnasal Sphenopalatine Ganglion Block in the Treatment of Chronic Migraine: A Double-blind Placebo-controlled Study[NCT01709708] | Phase 4 | 41 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| Greater Occipital Nerve Block for Migraine Prophylaxis[NCT00915473] | Phase 4 | 70 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| Placebo-Controlled Randomized Double Blind Trial of Blocking Greater Occipital Nerve Block With Bupivacaine Versus Saline in the Treatment of Chronic Migraine[NCT02578719] | Phase 4 | 0 participants (Actual) | Interventional | 2016-07-31 | Withdrawn (stopped due to Local Drug Authority didn't give permission to start.) | ||
| Comparison of Heated vs. Pulsed Radiofrequency Treatment of the Genicular Nerves for Osteoarthritis Knee Pain[NCT04379895] | 60 participants (Anticipated) | Interventional | 2020-06-30 | Not yet recruiting | |||
| A Comparison of Pain Control AND Quality of Life Improvement Between Occipital Nerve Block And Occipital Nerve Radiofrequency Ablation: A Double-Blind Single Center Prospective Study[NCT04124458] | 70 participants (Anticipated) | Interventional | 2023-01-02 | Not yet recruiting | |||
| Pulsed vs Continuous Radiofrequency Neurotomy for Cervical Facet Joint Mediated Pain: a Single-blind Randomized Controlled Clinical Trial[NCT04124445] | 88 participants (Anticipated) | Interventional | 2020-02-10 | Recruiting | |||
| Randomized, Double-blind, Comparative-effectiveness Study Comparing Corticosteroid Injections to Pulsed Radiofrequency for Occipital Neuralgia[NCT01670825] | 81 participants (Actual) | Interventional | 2012-08-31 | Completed | |||
| Greater Occipital Nerve Pulsed Radiofrequency for the Treatment of Combined Migraine and Cervicogenic Headache (New Approach): Randomized Clinical Trial[NCT06121037] | 60 participants (Actual) | Interventional | 2022-01-01 | Completed | |||
| Comparison of Great Occipital Nerve and Supraorbital Nerve Blockade Treatment Methods Individually and in Combination With Placebo in an Acute Migraine Attack in the Emergency Department, a Prospective, Double Blind, Randomized Controlled Study[NCT04491474] | Phase 4 | 128 participants (Actual) | Interventional | 2020-08-15 | Completed | ||
| Effects of Anesthetic Blockades on Pain Modulation in Migraine[NCT02188394] | Phase 2 | 36 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Ultrasound Guided Platelet Rich Plasma Injections for Post Traumatic Greater Occipital Neuralgia: A Randomized Controlled Pilot Study[NCT04051203] | Phase 1 | 35 participants (Anticipated) | Interventional | 2019-02-01 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT03951649)
Timeframe: 7 days
| Intervention | days (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 4 |
(NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 7 |
| Oral Acetaminophen/Caffeine Group | 2 |
Other: Pain at injection site (NCT03951649)
Timeframe: 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 2 |
(NCT03951649)
Timeframe: 7 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 0 |
| Oral Acetaminophen/Caffeine Group | 0 |
(NCT03951649)
Timeframe: 4 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 9 |
| Oral Acetaminophen/Caffeine Group | 14 |
(NCT03951649)
Timeframe: 5 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 4 |
| Oral Acetaminophen/Caffeine Group | 2 |
Emergency department for treatment of headache since treatment asked at 28 day follow up (NCT03951649)
Timeframe: 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 1 |
(NCT03951649)
Timeframe: 120 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 5 |
| Oral Acetaminophen/Caffeine Group | 5 |
Based on guidelines from the International Headache Society the primary outcome is the portion of women who experience resolution of headache or improvement of headache to mild range (VRS ≤ 3) at 2 hours following treatment with Occipital nerve block as compared to acetaminophen/caffeine cocktail. (NCT03951649)
Timeframe: 60-300 min
| Intervention | Participants (Count of Participants) |
|---|---|
| Occipital Nerve Block | 20 |
| Oral Acetaminophen/Caffeine Group | 16 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 60 min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 3 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 180min
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6 |
| Oral Acetaminophen/Caffeine Group | 4 |
"Visual/verbal Rating Score (VRS). VRS is used to assess pain in patients. With 0 representing no pain at all and 10 representing worst possible pain.~Total Minimum score=0 Total Maximum score=10~Higher values represent worse pain. If VRS=0, then the headache pain is considered resolved." (NCT03951649)
Timeframe: 2 hrs
| Intervention | score on a scale (Median) |
|---|---|
| Occipital Nerve Block | 6.0 |
| Oral Acetaminophen/Caffeine Group | 6.5 |
Number of acute medications used during Treatment period (6 weeks) and Follow-Up (4 weeks) (Group A vs. Group B). (NCT01709708)
Timeframe: 10 Weeks
| Intervention | Number of medications used (Mean) |
|---|---|
| Marcaine | 29.3 |
| Saline | 47.4 |
Number of adverse events over the entire length of study (Group A vs. Group B). (NCT01709708)
Timeframe: 34 weeks
| Intervention | Number of Adverse Events (Mean) |
|---|---|
| Marcaine | 7.67 |
| Saline | 5.29 |
Compare percentage change in Numeric Rating Scale (NRS) score from Before Procedure to 15-Minutes, Before Procedure to 30-Minutes, Before Procedure to 24-Hours After Procedure for all 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. (NCT01709708)
Timeframe: 15 Minutes Post Treatment, 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
| Intervention | percentage of change (Mean) | ||
|---|---|---|---|
| 15 Minutes Post Treatment | 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | -23.3 | -27.7 | -15.5 |
| Saline | -4.31 | -5.41 | 13.5 |
"Total Headache Impact Test (HIT-6) scores Pre-Treatment at Visit 2 vs. Post-Treatment (following final treatment), and at 1-Month Post-Treatment (Group A vs. Group B). HIT-6 is a series of 6 likert scale questions ranging from 1 to 5 with 1 being never and 5 being always. The HIT-6 answer options are weighted as follows: Never (1) = 6 points each, Rarely (2) = 9 points each, Sometimes (3) = 10 points each, Very often (4) = 11 points each, Always (5) = 13 points each. The total score for the HIT-6 ranges from 36 (subject answers all 6 questions as Never) to 78 subject answers all 6 questions as Always), with higher total scores indicating more impact than lower scores, i.e., headaches cause greater impact on the subject's life." (NCT01709708)
Timeframe: 10 Weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Pre-Treatment | Post-Treatment | 1-Month Post-Treatment | |
| Marcaine | 64.36 | 59.85 | 59.23 |
| Saline | 64 | 62.5 | 61.92 |
Compare change in the number of migraine headache days per month reported in Baseline Period Diary vs. Treatment Period Diary vs. Post-Treatment Period Diary. (NCT01709708)
Timeframe: 12 Weeks
| Intervention | Migraine headache days per month (Mean) | ||
|---|---|---|---|
| Baseline | Treatment | Post Treatment | |
| Marcaine | 15.0 | 12.3 | 10.8 |
| Saline | 15.8 | 12.2 | 11.3 |
Compare Modified Pain Characteristic Questionnaire scores Before Procedure vs. 24-Hour After Procedure, Before Procedure vs. 1-Month Follow Up, and Before Procedure vs. 6-Month Follow Up (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). The modified pain characteristic questionnaire is a series of 11 questions on a likert scale ranging from 0 to 10 with 0 being no pain or does not interfere and 10 being worst pain or completely interferes. Percentage questions range from 0 to 100. (NCT01709708)
Timeframe: Before Treatment, 24 Hours After Treatment, 1 Month Post Treatment, and 6 Months Post Treatment
| Intervention | units on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Worst Pain Question: Before Treatment | Worst Pain Question: 24 Hours After Treatment | Worst Pain Question: 1 Month Post Treatment | Worst Pain Question: 6 Months Post Treatment | Least Pain Question: Before Treatment | Least Pain Question: 24 Hours After Treatment | Least Pain Question: 1 Month Post Treatment | Least Pain Question: 6 Months Post Treatment | Average Pain Question: Before Treatment | Average Pain Question: 24 Hours After Treatment | Average Pain Question: 1 Month Post Treatment | Average Pain Question: 6 Months Post Treatment | Percent Relief Question: Before Treatment | Percent Relief Question: 24 Hours After Treatment | Percent Relief Question: 1 Month Post Treatment | Percent Relief Question: 6 Months Post Treatment | General Activity Question: Before Treatment | General Activity Question: 24 Hours After Treatmen | General Activity Question: 1 Month Post Treatment | General Activity Question: 6 Months Post Treatment | Mood Interference Question: Before Treatment | Mood Interference Question: 24 Hours After Treatme | Mood Interference Question: 1 Month Post Treatment | Mood Interference Question: 6 Months Post Treatmen | Walking Ability Question: Before Treatment | Walking Ability Question: 24 Hours After Treatment | Walking Ability Question: 1 Month Post Treatment | Walking Ability Question: 6 Months Post Treatment | Normal Work Question: Before Treatment | Normal Work Question: 24 Hours After Treatment | Normal Work Question: 1 Month Post Treatment | Normal Work Question: 6 Months Post Treatment | Relationships Question: Before Treatment | Relationships Question: 24 Hours After Treatment | Relationships Question: 1 Month Post Treatment | Relationships Question: 6 Months Post Treatment | Sleep Interference Question: Before Treatment | Sleep Interfere Question: 24 Hours After Treatment | Sleep Interferenc Question: 1 Month Post Treatment | Sleep Interference Question: 6 Months Post Treatme | Enjoyment Question: Before Treatment | Enjoyment Question: 24 Hours After Treatment | Enjoyment Question: 1 Month Post Treatment | Enjoyment Question: 6 Months Post Treatment | |
| Marcaine | 4.75 | 4.36 | 4.56 | 4.27 | 2.01 | 1.77 | 1.88 | 1.68 | 3.39 | 3.07 | 3.36 | 2.86 | 41.3 | 46.0 | 46.3 | 34.7 | 2.49 | 2.31 | 2.64 | 2.68 | 2.57 | 2.42 | 2.96 | 3.18 | 0.63 | 0.54 | 0.80 | 0.45 | 2.53 | 2.21 | 2.52 | 2.59 | 2.00 | 1.96 | 2.36 | 2.05 | 2.29 | 1.89 | 1.92 | 1.55 | 2.81 | 2.58 | 2.64 | 3.18 |
| Saline | 6.15 | 6.16 | 5.64 | 5.88 | 2.50 | 2.43 | 2.64 | 2.88 | 4.33 | 4.27 | 3.91 | 4.00 | 29.2 | 29.8 | 21.0 | 18.6 | 3.50 | 3.64 | 3.91 | 4.00 | 3.78 | 4.19 | 3.82 | 5.71 | 1.27 | 1.24 | 0.55 | 0.43 | 3.49 | 3.63 | 3.45 | 3.71 | 3.47 | 3.90 | 3.09 | 3.86 | 2.68 | 2.85 | 2.55 | 3.14 | 3.12 | 3.34 | 3.09 | 4.00 |
Compare Numeric Rating Scale (NRS) scores Before Procedure,15-Minute Post Treatment, 30-Minutes Post Treatment, 24-Hour Post Treatment for all 12 treatments (Marcaine vs. Saline). NRS is a likert scale ranging from 0-10 with 0 being no pain and 10 being worst possible pain. For each individual time point, all 12 treatments were averaged for that time point and a single value was used for comparison between the two groups. (NCT01709708)
Timeframe: 6 Weeks
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Before Procedure | 15 Minutes Post Treatment | 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | 3.18 | 2.53 | 2.41 | 2.85 |
| Saline | 3.78 | 3.51 | 3.45 | 4.20 |
Satisfaction scores Visit 2 vs. following treatment (Treatment 12) and at 1-Month Post-Treatment (Group A vs. Group B). Satisfaction scores are a likert scale ranging from 1 to 5 with 1 being complete dissatisfaction and 5 being complete satisfaction. (NCT01709708)
Timeframe: 10 Weeks
| Intervention | units on a scale (Mean) | ||
|---|---|---|---|
| Visit 2 | Following treatment (Treatment 12) | 1-Month Post-Treatment | |
| Marcaine | 3.52 | 3.55 | 3.57 |
| Saline | 3.00 | 2.50 | 2.64 |
Compare 24-Hour After Procedure Patient's Global Impression of Change (PGIC) score for 12 treatments (Mean of all 12 treatments for each timepoint, comparing Group A to Group B). PGIC is a likert scale ranging from 1 to 7 with 1 being very much improved and 7 being very much worse. (NCT01709708)
Timeframe: 30 minutes Post Treatment and 24 hours Post Treatment, assessed up to 6 weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 30 Minutes Post Treatment | 24 Hours Post Treatment | |
| Marcaine | 3.00 | 3.08 |
| Saline | 3.72 | 3.88 |
"Acute medication use meant the consumption of a drug to abort or terminate a headache." (NCT00915473)
Timeframe: 4 weeks post-injection
| Intervention | days per 4 weeks (Mean) |
|---|---|
| Active Injection | 6.7 |
| Placebo Injection | 7.7 |
(NCT00915473)
Timeframe: 4 weeks post-injection
| Intervention | hours per 4 weeks (Mean) |
|---|---|
| Active Injection | 60 |
| Placebo Injection | 58 |
The baseline frequency will be the number of calendar days with moderate or severe migraine during the 4 week period prior to injection, and the follow-up frequency will be the number of calendar days with migraine during the 4 week period following injection. (NCT00915473)
Timeframe: 4 weeks pre-injection baseline, 4 weeks post-injection
| Intervention | participants (Number) |
|---|---|
| Active Injection | 10 |
| Placebo Injection | 9 |
(NCT00915473)
Timeframe: 4 weeks post-injection
| Intervention | days per 4 weeks (Mean) | ||
|---|---|---|---|
| Severe | At Least Moderate | At Least Mild | |
| Active Injection | 3.4 | 7.0 | 9.3 |
| Placebo Injection | 2.9 | 7.8 | 10.4 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.495 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.694 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.791 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.441 |
The change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.312 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.765 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.068 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 3.738 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.392 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.220 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.000 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.694 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 3.678 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 4.410 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.540 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.650 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.522 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.417 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.761 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.556 |
This outcome measures the change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.583 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.825 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.539 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.069 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 9.256 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 9.431 |
This outcome will measure the participant's perceived improvement in sleep using the Athens Insomnia Scale. Scores in this scale can range from 0 to 24. 0 being the best possible outcome and 24 being the worst possible outcome. A score greater than or equal to 6 indicates a presence of insomnia. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 10.025 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 8.132 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 11.333 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 11.972 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.590 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 12.250 |
This outcome will measure the change in severity of depression using the Beck's Depression Inventory. Scores in this inventory can range from 0 to 63. 0 being the best possible outcome and 63 being the worst possible outcome. A score between 14 and 19 indicates mild depression and a score greater than or equal 29 indicates severe depression. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 12.775 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 10.842 |
This outcome measures the change in the numeric pain scale score from baseline to 2 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 2 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 4.726 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 5.846 |
This outcome measures the change in the numeric pain scale score from baseline to 3 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.850 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.149 |
This outcome measures the change in the numeric pain scale score from baseline to 6 months after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 6.705 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 7.541 |
The change in the numeric pain scale score from baseline to 6 weeks after treatment. The scale ranges from 0-10. The minimum score is 0 which is defined as no pain and the maximum score is 10, which is defined as the worst pain imaginable. The best possible outcome would be a 0. The worst possible outcome would be a 10. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 5.354 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 6.064 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.718 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 60.556 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 59.641 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 61.389 |
This outcome measures what the patient feels they cannot do because headaches. This outcome is measured using the Headache Impact Test. Scores in this test range from range from 36 to 78, with higher scores indicating greater negative impact. A score of less than 50 indicates minimal impact, while a score greater than or equal to 60 indicates headaches are severely impacting one's life. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | units on a scale (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 60.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 59.553 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 3 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 3 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.087 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.263 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 month follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.044 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.368 |
This outcome will measure the number of days the patient has severe migraine headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.708 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.810 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: 3 months
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.846 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.919 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 months after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 2.128 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 2.162 |
This outcome will measure the number of days the patient has severe occipital neuralgia headaches in the week (7 days) prior to the 6 week follow-up visit. A severe headache is defined as a headache with a score greater than or equal to 7 on the numeric pain scale. (NCT01670825)
Timeframe: From baseline to 6 weeks after the start of treatment
| Intervention | days (Mean) |
|---|---|
| Pulsed Radiofrequency + Local Anesthetic Injection | 1.436 |
| Corticosteroid Injection + Sham Pulsed Radiofrequency | 1.436 |
12 trials available for bupivacaine and Migraine Disorders
14 other studies available for bupivacaine and Migraine Disorders
| Article | Year |
|---|---|
A comparison of the clinical efficacy of GON block at the C2 level and GON block at the classical distal occipital level in the treatment of migraine.
Topics: Analgesics; Anesthetics, Local; Bupivacaine; Headache; Humans; Migraine Disorders; Nerve Block; Retr | 2022 |
Are more nerve injections in the same session more effective in migraine treatment? 3-month follow-up results.
Topics: Anesthetics, Local; Bupivacaine; Follow-Up Studies; Headache; Humans; Migraine Disorders; Nerve Bloc | 2022 |
Three men in a boat: The comparison of the combination therapy of botulinum toxin and greater occipital nerve block with bupivacaine, with botulinum toxin monotherapy in the management of chronic migraine.
Topics: Adult; Botulinum Toxins, Type A; Bupivacaine; Humans; Male; Migraine Disorders; Nerve Block; Quality | 2023 |
Evaluation of Occipital Nerve Blocks for Acute Pain Relief of Migraines.
Topics: Acute Pain; Adult; Aged; Anesthetics, Local; Bupivacaine; Dexamethasone; Female; Florida; Glucocorti | 2020 |
A randomized, double-dummy, emergency department-based study of greater occipital nerve block with bupivacaine versus intravenous metoclopramide for treatment of migraine: A comment.
Topics: Anesthetics, Local; Bupivacaine; Emergency Service, Hospital; Humans; Metoclopramide; Migraine Disor | 2021 |
What Is the Optimal Placebo for Clinical Trials of Nerve Blocks in Headache?: An N-of-1 Study of Lactated Ringer's.
Topics: Bupivacaine; Emergency Service, Hospital; Headache; Humans; Metoclopramide; Migraine Disorders; Nerv | 2019 |
Efficacy of the greater occipital nerve block in recurrent migraine type headaches.
Topics: Adult; Anesthetics, Local; Bupivacaine; Female; Follow-Up Studies; Humans; Middle Aged; Migraine Dis | 2016 |
Efficacy of the greater occipital nerve block in recurrent migraine type headaches.
Topics: Adult; Anesthetics, Local; Bupivacaine; Female; Follow-Up Studies; Humans; Middle Aged; Migraine Dis | 2016 |
Efficacy of the greater occipital nerve block in recurrent migraine type headaches.
Topics: Adult; Anesthetics, Local; Bupivacaine; Female; Follow-Up Studies; Humans; Middle Aged; Migraine Dis | 2016 |
Efficacy of the greater occipital nerve block in recurrent migraine type headaches.
Topics: Adult; Anesthetics, Local; Bupivacaine; Female; Follow-Up Studies; Humans; Middle Aged; Migraine Dis | 2016 |
Do bilateral and unilateral greater occipital nerve block effectiveness differ in chronic migraine patients?
Topics: Adult; Aged; Anesthetics, Local; Bupivacaine; Chronic Disease; Comorbidity; Female; Functional Later | 2017 |
[Hemicrania continua: characteristics and therapeutic experience in a series of 36 patients].
Topics: Adolescent; Adult; Age of Onset; Aged; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; | 2012 |
Death during transforaminal epidural steroid nerve root block (C7) due to perforation of the left vertebral artery.
Topics: Adult; Anesthetics, Local; Anti-Inflammatory Agents; Brain Edema; Bupivacaine; Fatal Outcome; Female | 2003 |
Treatment of primary headache in the emergency department.
Topics: Anesthetics, Local; Bupivacaine; Emergency Service, Hospital; Headache; Humans; Injections, Intramus | 2004 |
Cervicogenic headache in patients with presumed migraine: missed diagnosis or misdiagnosis?
Topics: Adult; Aged; Anesthetics, Local; Bupivacaine; Cervical Plexus; Cervical Vertebrae; Chronic Disease; | 2005 |
Greater occipital nevre block in migraine headache: preliminary results of 10 patients.
Topics: Analgesics; Anesthetics, Local; Bupivacaine; Dosage Forms; Dose-Response Relationship, Drug; Female; | 2008 |
Chronic paroxysmal hemicrania. X. On the autonomic involvement.
Topics: Atropine; Autonomic Nerve Block; Autonomic Nervous System; Bupivacaine; Chronic Disease; Cornea; Fem | 1986 |